secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bioventus Inc. (BVS)
CIK:        0001665988
Form:       8-K
Filed at:   2023-05-26T23:59:59+00:00
Accession:  0001628280-23-019872
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioventus completes sale of Wound Business for $35M cash + up to $45M earn-out; net ~$30M for debt
--------------------------------------------------------------------------------

- Closed divestiture of TheraSkin and TheraGenesis to LifeNet Health on May 22, 2023.
- Received $35M cash at close, $5M deferred 18 months, up to $45M earn-out through 2026.
- Net proceeds of ~$30M after adjustments and fees used to repay existing debt.
- Exclusive Sales Agent Agreement gives LifeNet Health rights to SonicOne in US and Canada.
- Pro forma Q1 2023 net sales from continuing ops $112.2M; net loss from cont ops $78.2M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1665988/000162828023019872/0001628280-23-019872-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1665988/000162828023019872/bvs-20230522.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-019872

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer